Chetana Pendkar
Critical Care Medicine · Brooklyn, NYNPI 1629525175
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.3%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $4,606 and has fallen 96.2% since, to $173 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $140.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Olympus Corporation Of The Americas$2K
- United Therapeutics Corporation$271
- Abiomed$269
- AstraZeneca$200
- Boston Scientific$66
- plus $128 from 4 others
What the payments were for
- Travel & lodging$3,60052%
- Food & beverage$1,29019%
- Education$2,00029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $4,238 |
| Olympus Corporation Of The Americas | 16 | $1,718 |
| United Therapeutics Corporation | 2 | $271 |
| Abiomed | 2 | $269 |
| AstraZeneca | 4 | $200 |
| Boston Scientific | 1 | $66 |
| Boehringer Ingelheim | 2 | $57 |
| GSK | 1 | $26 |
| Sanofi | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,759
- Spiration Valve System$429
- TYVASO$271
- Impella$269
How this compares
$6,890 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso Refill KitTreprostinil/Neb Accessories | 13 | $265,827 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 341 | $192,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 149 | $122,067 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 152 | $114,546 |
| Spiriva RespimatTiotropium Bromide | 53 | $36,037 |
| Incruse ElliptaUmeclidinium Bromide | 91 | $35,053 |
| Spiriva HandihalerTiotropium Bromide | 49 | $33,326 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $24,956 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $18,277 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $16,771 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $14,561 |
| Tiotropium Bromide | 28 | $11,280 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 327 | $10,259 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 38 | $9,678 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $8,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $57 | $236,755405 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $26 | $198,846326 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $200 | $136,900205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Brooklyn
- Joshua RosenbergBrooklyn$881K
- Mohammad ZamanBrooklyn$13K
- Yizhak KupferBrooklyn$8K
- Steven BadinBrooklyn$5K
- Daniel BuchneaBrooklyn$4K
- Samir FahmyBrooklyn$4K
- Alibel BelloBrooklyn$4K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.